- Home
- CTO vs SLS Comparison
CTO vs SLS Comparison
Compare CTO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | SLS |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 706.7M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | CTO | SLS |
|---|---|---|
| Price | $19.58 | $6.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $21.50 | $7.00 |
| AVG Volume (30 Days) | 256.1K | ★ 5.5M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.07 | $0.95 |
| 52 Week High | $20.25 | $5.66 |
Technical Indicators
Market Signals| Indicator | CTO | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 75.40 |
| Support Level | $17.29 | $1.48 |
| Resistance Level | $20.25 | N/A |
| Average True Range (ATR) | 0.42 | 0.50 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 48.53 | 96.89 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.